Print this page    •   Back to Web version of article

CROI 2012: New Version of Tenofovir May Be Safer and More Suppressive

March 26, 2012

Early study results show a good deal of promise for GS-7340, a newer form of tenofovir. The GS-7340 dose is about 10 times less than Viread, it appears to control HIV better, and it may help reduce side effects currently seen with Viread. GS-7340 will also be studied in a single pill regimen (with cobisistat, Prezista and Emtriva) as well as a replacement for Viread in the upcoming Quad pill.

In a small study of 38 people over 10 days, three doses of GS-7340 were given: 8, 25 and 40mg, compared to the regular dose of Viread. CD4 counts averaged 450. Everyone had viral loads >2,000 copies with no signs of resistance.

The researchers looked at how much viral load had decreased on day 11: placebo (0.07 log), Viread (0.97 log), 8mg (1.08 log), 25mg (1.46 log) and 40mg (1.73 log). Also promising were the lower blood concentration of GS-7340 (79% on 25mg and 98% on 40mg) which could mean fewer side effects including less kidney damage, as well as the higher cellular concentration of GS-7340 (20 times higher on 40mg) which could mean longer and more suppressive control of HIV over time.

The company that makes GS-7340 is moving the 25mg dose forward in other study.




This article was provided by Project Inform. You can find this article online by typing this address into your Web browser:
http://www.thebody.com/content/66982/croi-2012-new-version-of-tenofovir-may-be-safer-an.html

General Disclaimer: TheBody.com is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through TheBody.com should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.